For the numerous cardiology clinical practices in Japan, nuclear cardiology imaging tests are among the most important diagnostic tools. The Japanese nuclear cardiology community has developed a new application using 
B
ased on the Japanese ISOTOPE Foundation survey, 1,170 facilities performed nuclear medicine tests in 2012.
The population of Japan is currently 125 million, with 0.94 nuclear facilities per 100,000 population. Twenty-five percent of those facilities (296 of 1, 170) performed PET studies.
Among them, 104 performed PET only, and the remaining 192 performed both PET and SPECT (1, 2) .
Nuclear cardiology practice in Japan
The 2012 Japanese ISOTOPE Foundation survey showed the total number of nuclear cardiology studies performed as 31,475, an 11.0% decrease compared to the number in the for myocardial viability and cardiac sarcoidosis testing (Table   1 ) (2,5). Unlike the earlier approval of SPECT imaging, in the case of PET imaging, JMHLW approval was contingent upon some conditions. Currently standard hybrid PET/computed tomography (CT) scanners use CT for attenuation correction.
However, for cardiac PET, only the PET part is reimbursed even when a PET/CT scanner is used, and the simultaneously performed CT study is not reimbursed. 13 N-NH3 PET MPI is Annals of Nuclear Cardiology Vol. 
Conclusions
Current nuclear cardiology practice in Japan resembles that in North America but specifically differs in that 123 I-tracers imaging and 18 F-FDG PET have been approved for the diagnosis of cardiac sarcoidosis, differences that may be worthy of consideration for nuclear cardiology practice worldwide.
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